Abstract
A simple, rapid, selective, and reproducible reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for the estimation of Losartan potassium in dissolution samples of Losartan potassium immediate and sustained release tablets. Analysis was performed on an Agilent, Zorbax Eclipse XDB C18 column (150 mm × 4.6 mm, 5 μm) with the mobile phase consisting of orthophosphoric acid (0.1% v/v)—acetonitrile (55 : 45, v/v) at a flow rate of 1.0 mL/min. UV detection was performed at 225 nm and the retention time for Losartan was about 2.6 minutes. The calibration curve was linear (correlation coefficient = 0.999) in the selected range of analyte. The optimized dissolution conditions include the USP apparatus 2 at a paddle rotation rate of 50 rpm and 900 mL of pH 6.8 phosphate buffer as dissolution medium, at 37.0±0.5∘C. The method was validated for precision, linearity, specificity, accuracy, limit of quantitation, and ruggedness. The system suitability parameters, such as theoretical plate, tailing factor and relative standard deviation (RSD) between five standard replicates, were well within the limits. The stability result shows that the drug is stable in the prescribed dissolution medium.
Highlights
Dissolution is an official test routinely used in Quality Control (QC) and Research and Development (R and D) Laboratories for the evaluation of pharmaceutical products
This paper described a new reversed-phase high performance liquid chromatographic (RP-HPLC) method for the estimation of Losartan potassium in dissolution samples using simple mobile phase
PH 6.8 phosphate buffer was selected as the best dissolution medium
Summary
Dissolution is an official test routinely used in Quality Control (QC) and Research and Development (R and D) Laboratories for the evaluation of pharmaceutical products. The purpose of in vitro dissolution studies in QC is to check batch to batch consistency and detection of manufacturing deviation while in R and D the focus is to provide some predictive estimate of the drug release in respect to the in vivo performance of a drug product [1]. Losartan potassium is chemically 2-butyl-4-chloro1-[p-(o-1H-tetrazol-5-yl-phenyl)benzyl]-imidazole-5methanol monopotassium salt (Figure 1) [2]. It is an angiotensin II receptor blocker and chemically is used as an antihypertensive agent [3]. Losartan potassium is marketed alone or combined with hydrochlorothiazide
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
